Brukinsa™ (zanubrutinib) – New orphan drug approval
November 14, 2019 - The FDA announced the approval of BeiGene’s Brukinsa (zanubrutinib), for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Download PDF
